Study of the Sars-Cov2 Neuroinvasiveness - COVID19

Fondation Ophtalmologique Adolphe de Rothschild2 enrolled

Overview

Sars-Cov2 (COVID-19) may invade the CNS inducing neurological diseases such as anosmia, ageusia, encephalitis, ischemic or hemorrhagic stroke. Management of severe neurological complications in COVID-19 patients may require ventricular cerebrospinal fluid drainage and cranial decompression. During surgery, cerebrospinal fluid, meninges and brain parenchyma can be safely removed from the patient. In this study, COVID-19 patients will be evaluated first, for the presence of Sars-Cov2 in the cerebrospinal fluid and/or biopsies and second, for the consequences of Sars-Cov2 neuroinfection in terms of inflammatory and immune responses.

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

COVID19

Interventions

Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsiesDRUG

Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * COVID-19 patients requiring an external ventricular drain, a decompressive craniectomy or an intracranial hematoma surgery Exclusion Criteria: * Pregnant or lactating women

Locations (1)

Fondation A de Rothschild

Paris, France

Outcomes

Primary Outcomes

Percentage of patients with COVID-19 positive samples/biopsies

COVID-19 RT-PCR test

Time frame: At the time of the inclusion

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.